logo
ManageEngine Enhances AD360 With Risk Exposure Management and Local User MFA Features to Strengthen Identity Threat Defenses

ManageEngine Enhances AD360 With Risk Exposure Management and Local User MFA Features to Strengthen Identity Threat Defenses

National Post22-07-2025
Article content
New Capabilities Help Enterprises Visualize Attack Paths, Enforce MFA on Unmanaged Local Accounts, and Align Identity Security With the Zero Trust Framework
Article content
The identity risk exposure management feature adds identity threat detection capabilities that help uncover how attackers could escalate privileges or move laterally within the environment
With local user MFA, enterprises can extend enterprise-grade MFA to previously unmanaged local accounts
Read about AD360's identity risk exposure management at https://mnge.it/riskexposuremgmt and local user MFA capabilities at https://mnge.it/local-user-mfa
Article content
AUSTIN, Texas — ManageEngine, a division of Zoho Corporation and a leading provider of enterprise IT management solutions, today announced the general availability of identity risk exposure management and local user MFA features in AD360, its converged identity and access management (IAM) platform. The release enables security teams to detect privilege escalation risks and secure unmanaged local accounts, two common identity attack vectors that attackers continue to exploit at scale.
Article content
Identity remains the primary attack vector in modern enterprises, as shown by Verizon's 2025 Data Breach Investigations Report, which found that credential abuse was the initial access vector in 22% of breaches. The report also highlighted widespread abuse of poorly managed local accounts and privilege paths across over 12,000 confirmed breaches.
Article content
'With this release, ManageEngine AD360 moves beyond traditional IAM by embedding identity threat defenses into core identity operations. By turning identity data into actionable security insights, we're helping customers make IAM the first line of defense, not a check box,' said Manikandan Thangaraj, vice president of ManageEngine.
Article content
While most IAM tools focus on provisioning and policy enforcement, AD360 adds risk exposure mapping via attack path analysis as well as local MFA enforcement, helping enterprises close attack paths that often go undetected. This marks a key step in identity management evolving from an access control layer into an active security control.
New Capabilities
Article content
Identity risk exposure management: Graph‑based analysis maps lateral movement and privilege escalation paths in Active Directory (AD), automatically prioritizing risky configurations and recommending remediation steps. The graph engine models AD objects as nodes and privilege inheritance as lines, revealing multi‑step attack chains in real time, with actionable suggestions that IT teams can implement to close exposed paths.
Local user MFA: This feature extends adaptive MFA to local accounts on non‑domain‑joined servers, DMZ assets, and test environments, thwarting credential stuffing and persistence techniques.
ML‑driven access recommendations: During provisioning and access review campaigns, machine learning analyzes permission patterns and suggests adjustments to implement least privilege access, helping prevent excess entitlements.
Article content
Additionally, ManageEngine has enhanced AD360's access certification module, which now includes expanded entitlements for comprehensive review coverage, and the risk assessment capabilities feature new indicators for improved identity risk monitoring across AD and Microsoft 365 environments. These enhancements are designed to streamline compliance reporting and strengthen access governance across the enterprise. The new capabilities support NIST SP 800-207 on Zero Trust architecture, align with PCI DSS Version 4.0 Requirement 8, and facilitate SOX, HIPAA, and GDPR controls.
Article content
About AD360
Article content
ManageEngine AD360 is a unified identity platform that seamlessly connects people, technology, and experiences while giving enterprises full visibility and control over their identity infrastructure. It offers automated life cycle management; secure SSO; adaptive MFA; and risk-based governance, auditing, compliance, and identity analytics—all from a single, intuitive console. With extensive out-of-the-box integrations and support for custom connectors, AD360 easily integrates into existing IT ecosystems to enhance security and streamline identity operations. Trusted by leading enterprises across healthcare, finance, education, and government, AD360 simplifies identity management, fortifies security, and ensures compliance with evolving regulatory standards. For more information, please visit https://www.manageengine.com/active-directory-360/.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Media Contact:
Article content
Article content
Article content
Article content
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Globe and Mail

time12 minutes ago

  • Globe and Mail

Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

to explore external market opportunities as a potential revenue source. Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and potentially accelerating cancer immunotherapy development. to develop enhanced analytics and visualization tools, for the PredicTcell model to support its internal R&D teams. WARREN, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Tevogen ('Tevogen Bio Holdings Inc.' or 'Company') (Nasdaq: TVGN) today announced that its artificial intelligence initiative, is expanding its collaboration with Microsoft (Nasdaq: MSFT) and Databricks, to build the beta version of its foundational PredicTcell model. Powered by the Databricks Data Intelligence Platform and backed by their innovative engineering teams, has begun curating a dataset focused on oncology. The dataset, aggregated with the initial virology dataset. aims to improve upon the accuracy of the alpha version of PredicTcell model. This next phase of development builds on recently published international patent application (WO 2025/129197), which outlines novel machine learning systems for predicting immunologically active peptides, a critical step in developing targeted therapies for cancers and infectious diseases. 'We have been extremely fortunate to work with such great organizations like Microsoft and Databricks to build the alpha version of our foundational AI model,' said Mittul Mehta, Chief Information Officer and Head of 'Oncology represents one of the most impactful areas for AI in drug discovery, given the complexity of the disease and the limited availability of high-quality datasets.' Forward Looking Statements This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen's plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'possible,' 'potential,' 'goal,' 'opportunity,' 'project,' 'believe,' 'future,' and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

5 Reasons to Buy D-Wave Stock Like There's No Tomorrow
5 Reasons to Buy D-Wave Stock Like There's No Tomorrow

Globe and Mail

time12 minutes ago

  • Globe and Mail

5 Reasons to Buy D-Wave Stock Like There's No Tomorrow

D-Wave (NYSE: QBTS) is up 120% in 2025, driven by momentum involving its Advantage2 system and a major capital raise. But with negative cash flow and dilution concerns, is it the next tech rocket or a risky bet? I'll break down the facts so you can decide before Wall Street catches up. *Stock prices used were the market prices of Aug. 4, 2025. The video was published on Aug. 5, 2025. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,039%* — a market-crushing outperformance compared to 181% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025 Rick Orford has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Rick Orford is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link, they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.

The 3 Best Warren Buffett Stocks to Buy Right Now
The 3 Best Warren Buffett Stocks to Buy Right Now

Globe and Mail

time12 minutes ago

  • Globe and Mail

The 3 Best Warren Buffett Stocks to Buy Right Now

Key Points You can find wealth-building investments by perusing Berkshire Hathaway's well-stocked portfolio. Three of Buffett's most defensive stocks are particularly attractive buys today. 10 stocks we like better than Berkshire Hathaway › All good things must come to an end. After six decades generating fortunes for Berkshire Hathaway 's (NYSE: BRK.A)(NYSE: BRK.B) shareholders, Warren Buffett will soon relinquish his role as CEO of the trillion-dollar masterpiece of American capitalism he helped build. Fortunately, Buffett plans to remain chairman of Berkshire's Board of Directors and continue to help guide the company's major investment decisions. Better still, the legendary financier's best ideas continue to comprise the lion's share of the conglomerate's public stock holdings, currently valued at a staggering $280 billion. If you'd like to profit alongside Buffett, here are some of Berkshire's best stocks for today's turbulent economic environment. 1. Kroger When people pinch pennies, they dine out less and dine in more. The eat-from-home trend is a boon for Kroger (NYSE: KR), the largest pure play grocery chain in the U.S. With over 2,700 stores and roughly $150,000 billion in annual revenue, Kroger's impressive scale provides it with significant advantages over its smaller rivals. The grocery giant's purchasing power gives it an edge in pricing that cash-strapped consumers appreciate. Kroger can also afford to invest more aggressively in technology, which helped to fuel a 15% jump in the company's digital sales in the first quarter. All told, Kroger is the type of investment that will allow you to sleep easily at night while you own it. People need to eat, and the grocery leader's defensive business model generates consistent profits across economic cycles. Moreover, Kroger's bountiful free cash flow -- which management expects to climb as high as $3 billion in 2025 -- supports a steadily growing dividend and sizable share repurchases. These cash returns should continue to drive Kroger's stock price higher in the coming years. KR data by YCharts. 2. Coca-Cola Long-time Buffett favorite Coca-Cola (NYSE: KO) is another reliable dividend stock to consider adding to your diversified investment portfolio. The beverage colossus has increased its cash payments to shareholders for an extraordinary 63 consecutive years. If you're worried about Coca-Cola's reliance on sugary soda sales, fear not. The beverage king has worked to broaden its offerings to include healthier fare like milk, tea, and bottled water. Strong sales of high-protein drinks under the company's popular Fairlife brand are a notable growth driver. Coca-Cola Zero Sugar and other sugar-free drinks also remain top sellers among health-conscious consumers. Coca-Cola's diversified product lineup and strong free-cash-flow generation make it one of the most dependable dividend payers available in the stock market today. Buffett's beloved beverage maker is currently offering you a solid 3% yield. 3. Berkshire Hathaway The most defensive and safest business of all, however, may just be Berkshire Hathaway itself. Buffett's financial fortress is sitting on a massive cash stash of more than $340 billion just waiting to be deployed in value-creating investments on behalf of its shareowners. Berkshire's huge cash reserves enable it to pounce on profit opportunities as they arise. This typically occurs during volatile times. Buffett fans know this, which is one of the reasons why Berkshire's stock tends to outperform during bear markets. The megaconglomerate's diverse business segments further help to reduce the risks for investors. Berkshire owns more than 60 operating subsidiaries in areas as far-ranging as railroads, car insurance, ice cream, and underwear. BNSF Railway, GEICO, Dairy Queen, and Fruit of the Loom are just a small sample of Berkshire's assorted holdings. Together, these businesses cranked out over $10 billion in operating cash flow in Q1 alone. Although Buffett is stepping down as CEO at the end of 2025, he's handing over the reins to his hand-picked successor, Greg Abel. The longtime Berkshire executive isn't expected to rock the boat, as he's already overseeing many of the company's most important businesses. And the limited number of changes expected to come under Abel's leadership could prove beneficial. For example, Abel might be more aggressive with selling off Berkshire's few underperforming assets, such as its multibillion-dollar stake in Kraft Heinz. That could further swell the investment giant's already enormous cash reserves, thereby giving Berkshire even more capital to deploy during the next market downturn. Should you invest $1,000 in Berkshire Hathaway right now? Before you buy stock in Berkshire Hathaway, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Berkshire Hathaway wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $631,505!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,103,313!* Now, it's worth noting Stock Advisor's total average return is 1,039% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store